Circulating C1q/TNF-Related Protein 3, Omentin-1 and NGAL in Obese Patients with Type 2 Diabetes During Insulin Therapy

Abstract

The aim of the study was to quantify the plasma concentration of omentin-1, neutrophil gelatinase-associated lipocalin (NGAL), and complement C1q tumor necrosis factor-related protein-3 (CTRP3) in obese patients with type 2 diabetes, before introducing insulin therapy, in relation to the plasma expression profiles of these regulatory molecules in the same patients after a 6-month insulin mixture therapy and in obese controls. Elevated plasma NGAL concentrations were found in type 2 diabetic patients as compared with subjects with metabolically healthy obesity. In turn, a 6-month insulin mixture therapy has shown a marked increase in the plasma concentration of omentine-1 and a significant decrease in plasma CTRP3 concentration in obese patients with type 2 diabetes, in relation to the values found in these patients before the implementation of insulin therapy. Insulin mixture therapy has also proved to be an important factor modifying the plasma profile of NGAL, increasing the concentration of this bioactive molecule in the plasma of patients with type 2 diabetes, after 6 months of its use, in relation to the concentration before treatment. The significant changes in the plasma profile of omentin-1, NGAL and CTRP3 during insulin therapy suggest their potential diagnostic utility in monitoring metabolic changes associated with the introduction of insulin treatment in type 2 diabetic patients.

Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer’s disease associated with obesity, metabolic syndrome, and type 2 diabetes

“…LCN2 is a downstream TNF inflammatory molecule associated with hepatic steatosis and insulin insensitivity [32]. To gain further insight into the resultant immune alterations present in the gut-liver axis, we next assessed the hepatic LCN2 levels and the expression of inflammatory factors in the liver tissue.…”

Association between omentin-1 and indices of glucose metabolism in early pregnancy: a pilot study

“…Our ndings are consistent with the results of some previous studies examining the association between serum omentin-1 and glucose metabolism. Decreased omentin-1 has been observed in type 2 diabetes and impaired glucose tolerance [21,25,[31][32][33] while evidence for association between omentin-1 and type 1 diabetes are inconsistent [34][35][36][37]. This can be explained based on the association between accumulating risk factors such as obesity and central fat distribution with cardio-metabolic diseases, while type 1 diabetes has mainly a genetic etiology.…”

Effects of different obesity-related adipokines on the occurrence of obstructive sleep apnea

“…C1q/TNF-Related Protein-3 (CTRP3) is a recently discovered protein that has a deep structural homology to APN and can protect the organism against the effects of APN deficiency as well as maintain energetic homeostasis of the system [132]. Furthermore, CTRP3 has antiinflammatory activity, can inhibit the production of glucose and fat, and decreases lipotoxicity associated with abnormal fat deposition in peripheral tissues [133]. What role does it play when the serum levels of leptin and adiponectin change in patients with OSA?…”